Glucut 2 MT Tablet is a combination oral hypoglycemic agent containing Glimepiride 2 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby lowering blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, enhancing glucose uptake and utilization. The synergistic action of these two agents helps achieve better glycemic control in patients inadequately controlled on diet and exercise alone or on monotherapy. Glucut 2 MT is typically prescribed as part of a comprehensive diabetes management plan, including diet modification, physical activity, and regular monitoring of blood glucose levels. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and hypoglycemia. Regular monitoring of renal function and blood glucose is recommended during therapy. Dose adjustments should be individualized based on therapeutic response and tolerability. Glucut 2 MT offers an effective option for improving glycemic control in type 2 diabetes patients requiring dual oral therapy.